67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
Orlando, Florida, US 06 December 2025 - 09 December 2025
First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL
Single-agent pirtobrutinib significantly improved progression-free survival (PFS) vs bendamustine plus rituximab (BR) for patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the first results from the phase III BRUIN CLL-313 trial.
Molecular analysis supports ibrutinib-venetoclax in poor-risk CLL patients
Findings from the phase III NCRI* FLAIR** trial demonstrate the benefit of MRD***-guided ibrutinib + venetoclax (I+V) in chronic lymphocytic leukaemia (CLL) patients with gene aberrations compared with ibrutinib and fludarabine, cyclophosphamide, and rituximab (FCR).
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.
Does aspirin use improve outcomes in APS patients with arterial thrombosis?
The addition of low-dose aspirin to warfarin appears to increase the risk of major bleeding in patients with antiphospholipid syndrome (APS) but falls short in reducing all-cause mortality, according to a study presented at ASH 2025. Likewise, the rates of ischemic stroke and acute myocardial infarction are also higher among aspirin users.
